Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1125931

registered interest
date	10/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	England Infected Blood Support Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, from which budget in his Department the increase in funding for the England Infected Blood Support Scheme has been allocated.
tabling member constituency	Edinburgh East
tabling member printed	Tommy Sheppard
uin	252870
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>The Department undertakes a comprehensive annual planning exercise each year to allocate resources. The increase in infected blood payments was factored into this exercise for 2019/20 and scope was found to ensure that the costs can be met.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/05/2019 16:36:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4453 label Biography information for Tommy Sheppard

1125939

registered interest
date	10/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Students
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of NHS mental health support for university students.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	252889
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Mental health is a priority for this Government. That is why the Department of Health and Social Care is continuing to work closely with the Department for Education to improve the mental health of university students.</p><p> </p><p>To support this, the NHS Long Term Plan commits to a comprehensive expansion of mental health services, including a new approach to mental health services for people aged 18-25, supporting transitions to college and to adulthood, with services being adapted to create a comprehensive offer for 0 to 25 year olds.</p><p> </p><p>NHS England is working closely with Universities UK through the Mental Health in Higher Education programme to build the capability and capacity of universities to improve student welfare services and improve access to mental health services for the student population, including focusing on suicide reduction, and improving access to psychological therapies to support and treat students suffering from stress and anxiety.</p><p> </p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/05/2019 16:39:08 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1125944

registered interest
date	10/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Stem Cells: Donors
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to engage with BAME communities on stem cell donations.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	252891
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Since 2011 the Department has provided more than £26 million in financial support to NHS Blood and Transplant and Anthony Nolan to enable the establishment of a unified United Kingdom Stem Cell Registry and improve stem cell donation. This includes improving equity of access to unrelated donor stem cell transplantation for Black African Minority Ethnic (BAME) patients through targeted recruitment to the UK Stem Cell Registry and the Department has set specific targets about the proportion of donors that must be from BAME backgrounds.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/05/2019 16:37:40 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1124918

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that haemophilia patients receive (a) appropriate access to physiotherapy, (b) a regular clinical review, and (c) tailored dosing of treatments in accordance with NHS England’s service specification.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251321
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251322 251323 251324 question first answered 15/05/2019 16:14:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124919

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Commercial Medicines Unit’s national tender framework for factor VIII haemophilia products on patient access to extended half-life medicines.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251322
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251321 251323 251324 question first answered 15/05/2019 16:14:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124920

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Diseases: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he NHS England is taking to ensure that patients with bleeding disorders have adequate access to treatment options that meet individual patient need.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251323
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251321 251322 251324 question first answered 15/05/2019 16:14:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124921

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Haemophilia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of the adequacy of the availability of Haemtrack in Haemophilia centres.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251324
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251321 251322 251323 question first answered 15/05/2019 16:14:44 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124923

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Infectious Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231466 on Hospitals: Infectious Diseases, whether work of Public Health England will also include as assessment of the effect of changes to ophthalmic surgical practice on trends in the level of risk of infection rates in hospitals.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251326
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Public Health England does not currently include ophthalmic surgery as part of mandatory or voluntary surveillance of surgical site infections.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:24:36 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124924

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ophthalmic Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231467 on Ophthalmic Services, whether he has made an assessment of the ability for clinicians to take into account patients’ wishes for concomitant treatment in relation to potential restrictions of the 2019/2020 NHS Tariff.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	251327
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>For the 2017/19 national tariff (which was set for two years), the prices for BZ91 were manually increased above the initially modelled level (based on 2014/15 reference costs) following feedback from the ophthalmology Expert Working Group (EWG). For 2019/20, the EWG recommended that the prices for BZ91 should not be increased and should remain as modelled (based on 2016/17 reference costs).</p><p>The EWG also confirmed that minimally invasive glaucoma surgery (MIGS) and cataract activity are commonly done together and it would not usually be in the patient’s best interest to do them separately. The EWG advised that BZ91 was appropriate for combined MIGS and cataract activity – a MIGS procedure plus a cataract procedure should not receive over twice as much as either procedure alone.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:43:32 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1124938

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Education: Air Pollution
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department is making on producing a public information campaign to educate the general public on the health impacts of air pollution, particularly in instances of moderate or high pollution episodes.
tabling member constituency	Penistone and Stocksbridge
tabling member printed	Angela Smith
uin	251250
answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Public Health England and the Department for Environment, Food and Rural Affairs (Defra) are exploring whether social marketing can assist in awareness-raising about air pollution.</p><p>The Joint Air Quality Unit (JAQU) is planning a national-level campaign to support Clean Air Zones (CAZ) from summer 2019. This will raise awareness of the risks presented by high concentrations of nitrogen dioxide (NO2) and the implementation of charging CAZ. It will also promote long-term behaviour change by encouraging the public to change travel habits and reduce NO2 emissions.</p><p>The JAQU has also provided a CAZ communications toolkit to support local authorities in their local communications work. It contains key messages, frequently asked questions, useful statistics, infographics and other content to ensure a consistent approach is taken to raising awareness and to encourage drivers to consider alternative options in terms of travel and vehicle choice.</p><p>Defra is developing a communication strategy on domestic combustion for launch before the next winter burning season.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/05/2019 16:30:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1564 label Biography information for Angela Smith